Home
Green Cross

Green Cross Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domaingreencross.com

Year Founded--

Employees51 - 200

Annual Revenue--

Green Cross

Green Cross (including company regionals)

greencross.com

See more website traffic and engagement information

Total visits to Green Cross's top domains

Understand Green Cross market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

greencross.com25.8K

See more with Sales Intelligence

Avg. visit duration in Green Cross's top domains

Analyze Green Cross engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

greencross.com00:03:42

See more with Sales Intelligence

Avg. pageviews on Green Cross's top domains

See how Green Cross keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

greencross.com15.01

See more with Sales Intelligence

Green Cross top competitors by domain

Top similar sites in May 2026, ranked by their affinity

merckvaccines.comCompany NameMerck VaccinesEmployees51 - 200HQUnited States, Pennsylvania, West PointAnnual revenue$25M - $50MTotal visits31KHealth > Pharmacy

Top technologies used by Green Cross

These are the website technologies, by industry, used by Green Cross top domains

Social (2)

Instagram

Conversion & Analytics (1)

AceCounter

Mobile (1)

Apple Mobile Tags

News & Signals from Green Cross

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsGreen Cross hires Adams as interim CMO.Adams leaves his position as interim CMO at amaysim to join Greencross in her place and has congratulated McDermott on the work she had done to build a talented team, brand and customer platform during her time with the company.

NewsGreen Cross is developing maralixibat within South Korea.Under the terms of the licensing agreement, GC Pharma has obtained the exclusive right to develop and commercialize maralixibat within South Korea for ALGS, PFIC, and BA.

NewsGreen Cross is developing hyperimmune globulin drug for Covid-19.GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing results in phase 3 clinical trials.